XBIState Street SPDR S&P Biotech ETF
Tracks the total return performance of the S&P Biotechnology Select Industry Index.
By State Street Investment Management · Launched 2006
Annual Cost
0.35%
#1,645 of 5,853 · low cost
Fund Size
$10.7B
#265 of 5,853 · large
Return (1Y)Goal
+71.2%
Track Record
20 years
#260 of 5,853 · established
Performance
Total-return NAV · USDGrowth of $10,000
$15,100+51.0%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
North americaCap
Multi cap
Strategy
Index tracking
Sector
Health careFocus
Biotech & Genomics
Index tracked
S&P Biotechnology Select Industry Index
What it actually holds
By weightConcentration
Top 10 holdings = 20.4% of fund✓ well diversified
State Street Global Advisors
8.0%
Apellis Pharmaceuticals Inc
1.8%
Alkermes PLC
1.5%
Madrigal Pharmaceuticals Inc
1.4%
TG Therapeutics Inc
1.3%
Insmed Inc
1.3%
Scholar Rock Holding Corp
1.3%
Apogee Therapeutics Inc
1.3%
Protagonist Therapeutics Inc
1.2%
Summit Therapeutics Inc
1.2%
Asset allocation
Stocks
100.0%
Cash
0.0%
By sector
Healthcare
99.5%
Financial Services
0.5%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
27.0%High
Year-on-year price swings
Max drawdown
-63.9%Severe
Worst peak-to-trough loss
Sharpe (3Y)
0.70Decent risk-adjusted returns
Sortino (3Y)
1.03Good downside protection
Listing
- Exchange
- NYSE Arca
Full fund details
- Objective
- Tracks the total return performance of the S&P Biotechnology Select Industry Index.
- Strategy
- Invests primarily in U.S. biotechnology companies with float-adjusted market capitalizations of at least $500 million, using a sampling strategy to track the S&P Biotechnology Select Industry Index. The Fund may also invest in cash and cash equivalents for management purposes.
- Inception date
- January 31, 2006
- Fund family
- State Street Investment Management
Similar funds
Same asset class, closest by strategy & exposureWhat's next?
You've looked at XBI. Save it to your watchlist to weigh it against other funds, then turn your shortlist into a portfolio.
Data updated on 2026-08-02